State Street SPDR S&P Biotech ETF
349 hedge funds and large institutions have $3.77B invested in State Street SPDR S&P Biotech ETF in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 130 increasing their positions, 86 reducing their positions, and 34 closing their positions.
106% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 34
51% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 86
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
11% more funds holding
Funds holding: 314 → 349 (+35)
6.17% less ownership
Funds ownership: 96.31% → 90.14% (-6.2%)
37% less capital inflows, than outflows
Capital inflows: $418M | Capital outflows: $659M
49% less call options, than puts
Call options by funds: $777M | Put options by funds: $1.51B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
+$91.6M |
| 2 |
AssetMark Inc
Concord,
California
|
+$37.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$37M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$147M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$112M |
| 3 |
JP Morgan Chase
New York
|
-$80.5M |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$61.5M |
| 5 |
Goldman Sachs
New York
|
-$43.7M |
XBI Hedge Fund Activity: Q3 2017 in Review
349 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2017, worth a combined $3.77B — up 4.7% from $3.6B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new XBI positions and 34 closed out — a net gain of 36 holders — while 130 added to existing stakes and 86 trimmed.
The largest buyer was Credit Suisse, adding an estimated $91.6M. The largest seller was Citigroup, cutting an estimated $147M.
- 349 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2017, up from 314 in Q2 2017.
- Funds reported $3.77B of State Street SPDR S&P Biotech ETF stock for Q3 2017, up 4.7% quarter-over-quarter.
- 70 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2017 and 34 closed out, a net change of +36 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2017 was Credit Suisse, an estimated $91.6M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2017 was Citigroup, an estimated $147M sold.
Based on aggregated 13F filings for Q3 2017.